{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:44:55Z","timestamp":1790423095523,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> The study aimed to evaluate the impact of the National Health Insurance Coverage (NHIC) policy on the utilisation and accessibility of innovative anti-cancer medicines in Nanjing, China.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We used the adjusted World Health Organisation and Health Action International methodology to calculate the price and availability of 15 innovative anti-cancer medicines included in the National Health Insurance drug list in 20 tertiary hospitals and six secondary hospitals in Nanjing before and after NHIC policy implementation. Interrupted time-series regression was used to analyse the changes in the utilisation of the study medicines.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The price reduction rates of innovative anti-cancer medicines ranged between 34 and 65%. The mean availability rate was 27.44% before policy implementation and increased to 47.33% after policy implementation. The utilisation of anti-cancer medicines suddenly increased with a slope of 33.19\u20132,628.39 when the policy was implemented. Moreover, the usage rate of bevacizumab, bortezomib, and apatinib significantly increased (<jats:italic>p<\/jats:italic> &amp;lt; 0.001, <jats:italic>p<\/jats:italic> = 0.009, and <jats:italic>p<\/jats:italic> &amp;lt; 0.001, respectively) after policy implementation. With regard to price reduction and medical insurance reimbursement, the medicines became more affordable after policy implementation (0.06\u20131.90 times the per capita annual disposable income for urban patients and 0.13\u20134.46 times the per capita annual disposable income for rural patients).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The NHIC policy, which was released by the central government, effectively improved the utilisation and affordability of innovative anti-cancer medicines. However, the availability of innovative anti-cancer medicines in hospitals remained low and the utilisation of innovative anti-cancer medicines was affected by some factors, including the incidence of cancer, limitation of indications within the insurance program, and the rational use of innovative anti-cancer medicines. It is necessary to improve relevant supporting policies to promote the affordability of patients. The government should speed up the process of price negotiation to include more innovative anti-cancer medicines in the medical insurance coverage, consider including both medical examinations and adjuvant chemotherapy in the medical insurance, and increase investment in health care.<\/jats:p>","DOI":"10.3389\/fpubh.2021.714127","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T07:15:58Z","timestamp":1628234158000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Wenqing","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11735\/j.issn.1004-0242.2019.01.A001","article-title":"Report of cancer incidence and mortality in different areas of China, 2015","volume":"28","author":"Sun","year":"2019","journal-title":"China Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3969\/j.issn.1673-5390.2019.11","article-title":"The frontier and innovation of biomedicine in the new era","volume":"11","author":"Chen","year":"2019","journal-title":"China Food & Drug Administration Magazine."},{"key":"B3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jval.2011.05.004","article-title":"Patient access to new cancer drugs in the United States and Australia","volume":"14","author":"Wilson","year":"2011","journal-title":"Value in Health."},{"key":"B4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.7507\/1672-2531.201703028","article-title":"Accessibility of high-cost anti-cancer medicines in China","volume":"17","author":"Zhou","year":"2017","journal-title":"Chinese J Evidence-Based Med."},{"key":"B5","unstructured":"Opinions of the State Council on implementing the Health China Action2019"},{"key":"B6","unstructured":"Don't let innovative anti-cancer drugs become a mirror image, experts call for improving access to innovative drugs\n            LiY\n          Pharmaceutical Economic News2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Zwelling. Cancer drugs in the United States: Justum Pretium\u2014the just price","volume":"31","author":"Kantarjian","year":"2013","journal-title":"J Clini Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1377\/hlthaff.2014.0498","article-title":"Specialty pharmaceuticals: policy initiatives to improve assessment, pricing, prescription, and use","volume":"33","author":"Robinson","year":"2014","journal-title":"Health Aff."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1200\/JOP.17.00058","article-title":"Examining trends in cost and clinical benefit of novel anticancer drugs over time","volume":"14","author":"Saluja","year":"2018","journal-title":"J Oncol Pract"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/S0140-6736(16)31937-7","article-title":"Expenditure and financial burden for common cancers in China: a hospital-based multicentre cross-sectional study","volume":"388","author":"Huang","year":"2016","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.369\/j.issn.1674-3830.2016.3.009","article-title":"The exploration of medical insurance in precise poverty alleviation in inner Mongolia Bringing tumor targeting drugs into the payment of m4edical insurance","author":"Wang","year":"2016","journal-title":"Chinese Health Insurance"},{"key":"B12","unstructured":"China Society2015"},{"key":"B13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.29808","article-title":"Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors","volume":"122","author":"Kale","year":"2016","journal-title":"Cancer"},{"key":"B14","article-title":"Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries","volume-title":"In: Social Science Research Network.","author":"Knaul","year":"2011"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1002\/cncr.28262","article-title":"Are survivors who report cancer-related financial problems more likely to forgo or delay medical care?","volume":"119","author":"Kent","year":"2013","journal-title":"Cancer"},{"key":"B16","first-page":"51","article-title":"Special report on consumption upgrading series (ii): Access to anti-cancer medicines is increasing","volume":"21","author":"Ji","year":"2018","journal-title":"Modern Commercial Banking."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12885-017-3980-3","article-title":"Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan","volume":"18","author":"Sarwar","year":"2018","journal-title":"BMC Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.3390\/ijerph16193728","article-title":"Availability, price and affordability of anticancer medicines: evidence from two cross-sectional surveys in the Jiangsu Province, China","volume":"16","author":"Zhu","year":"2019","journal-title":"Int J Environ Res Public Health."},{"key":"B19","unstructured":"BollykyTJ\n          Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-Communicable Diseases2011"},{"key":"B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.7664\/CHE20170311","article-title":"Research on the evaluation of special drug policy in Changzhou, Jiangsu: taking HER-2 positive breast cancer as the example","volume":"36","author":"Yang","year":"2017","journal-title":"China Health Economics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.6039\/j.issn.1001-0408.2017.20.03","article-title":"Affordability evaluation for 3 kinds of anti-cancer medicines targeted drugs: Taking Hubei province as an example","volume":"28","author":"Tian","year":"2017","journal-title":"China Pharmacy."},{"key":"B22","doi-asserted-by":"publisher","first-page":"020702","DOI":"10.7189\/jogh.09.020603","article-title":"How government insurance coverage changed the utilisation and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study","volume":"9","author":"Diao","year":"2019","journal-title":"J Glob Health."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e002256","DOI":"10.1136\/bmjgh-2019-002256","article-title":"Using strategic price negotiations to contain costs and expand access to medicines in China","volume":"5","author":"Si","year":"2020","journal-title":"BMJ Glob Health."},{"key":"B24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1377\/hlthaff.2012.1268","article-title":"International best practices for negotiating \u2018reimbursement contracts' with price rebates from pharmaceutical companies","volume":"32","author":"Morgan","year":"2013","journal-title":"Health Aff(Millwood)."},{"key":"B25","unstructured":"Notice of Jiangsu provincial department of human resources and society on the inclusion of 36 drugs into list of basic medical insurance, industrial injury insurance and maternity insurance2017"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/ijerph16183479","article-title":"Healthcare Supply Chain Network Coordination Through Medical Insurance Strategies with Reference Price Effect","volume":"16","author":"Gao","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"B27","unstructured":"ChinaNanjing Statistical Yearbook 20182019"},{"key":"B28","unstructured":"A brief analysis of the causes of deaths from illnesses and injuries of Nanjing residents in 20172018"},{"key":"B29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/heapol\/czp056","article-title":"Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China","volume":"25","author":"Yang","year":"2010","journal-title":"Health Policy Plan"},{"key":"B30","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/heapol\/czy076","article-title":"The availability, price and affordability of antidiabetic drugs in Hubei province, China","volume":"33","author":"Gong","year":"2018","journal-title":"Health Policy Plan"},{"key":"B31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4316","DOI":"10.3390\/ijerph16224316","article-title":"The effect of the full coverage of essential medicines policy on utilization and accessibility of primary healthcare service for rural seniors: a time series study in Qidong, China","volume":"16","author":"Wang","year":"2019","journal-title":"Int J Environ Res Public Health."},{"key":"B33","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1037\/0022-006X.61.6.966","article-title":"Interrupted time-series analysis with brief single-subject data","volume":"61","author":"Crosbie","year":"1993","journal-title":"J Consult Clin Psychol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/01621459.1949.10483290","article-title":"Application of least squares regression to relationships containing auto-correlated error terms","author":"Orcutt","year":"1949","journal-title":"J Am Stat Assoc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jeconom.2007.06.003","article-title":"Robust estimation for structural spurious regressions and a Hausman-type cointegration test","volume":"142","author":"Choi","year":"2008","journal-title":"J Econometric."},{"key":"B36","doi-asserted-by":"publisher","first-page":"E39","DOI":"10.3390\/foods6060039","article-title":"Climate Change and Its Impact on the Yield of Major Food Crops: Evidence from Pakistan","volume":"6","author":"Ali","year":"2017","journal-title":"Foods"},{"key":"B37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1756-8722-5-67","article-title":"Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-na\u00efve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial","volume":"5","author":"Zinzani","year":"2012","journal-title":"J Hematol Oncol."},{"key":"B38","first-page":"692","article-title":"Chinese anti-cancer association. Guidelines and norms for the diagnosis and treatment of breast cancer in Chinese anti-cancer association","volume":"25","year":"2015","journal-title":"Chinese Oncology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.7150\/jca.15802","article-title":"The efficacy of bevacizumab in different line chemotherapy for chinese patients with metastatic colorectal cancer","volume":"7","author":"Yin","year":"2016","journal-title":"J Cancer."},{"key":"B40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jtho.2017.12.009","article-title":"Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study","volume":"13","author":"Scagliotti","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/annonc\/mdz020","article-title":"Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial","volume":"30","author":"Zhao","year":"2019","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00277-013-1893-z","article-title":"Lenalidomide with dexamethasone treatment for relapsed\/refractory myeloma patients in Korea-experience from 110 patients","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/cam4.2014","article-title":"Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"},{"key":"B49","unstructured":"ChinaNanjing Statistical Yearbook 20192020"},{"key":"B50","doi-asserted-by":"publisher","first-page":"FC17","DOI":"10.7860\/JCDR\/2016\/22384.8918","article-title":"Variation of Cost among Anti-cancer Drugs Available in Indian Market","volume":"10","author":"Kolasani","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/2224-3151.239415","article-title":"Approaches to improving access to essential cancer medicines in the WHO South-East Asia Region","volume":"7","author":"Chivukula","year":"2018","journal-title":"WHO South East Asia J Public Health."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.714127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T07:16:21Z","timestamp":1628234181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.714127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":51,"alternative-id":["10.3389\/fpubh.2021.714127"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.714127","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"article-number":"714127"}}